Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Mersana Therapeutics Inc (NASDAQ: MRSN) was $0.37 for the day, down -8.22% from the previous closing price of $0.40. In other words, the price has decreased by -$8.22 from its previous closing price. On the day, 1.79 million shares were traded.
Ratios:
Our analysis of MRSN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.19 and its Current Ratio is at 2.19.
JP Morgan Upgraded its Underweight to Neutral on March 19, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 16 ’25 when Mandelia Ashish sold 3,554 shares for $0.58 per share. The transaction valued at 2,061 led to the insider holds 57,519 shares of the business.
Protopapas Anna sold 8,637 shares of MRSN for $5,009 on Jan 16 ’25. The Director now owns 168,041 shares after completing the transaction at $0.58 per share. On Jan 16 ’25, another insider, Lowinger Timothy B, who serves as the SVP, Chief Sci.&Tech. Officer of the company, sold 8,048 shares for $0.58 each. As a result, the insider received 4,668 and left with 257,673 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.12.
Stock Price History:
Over the past 52 weeks, MRSN has reached a high of $3.63, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is -11.44%, while the 200-Day Moving Average is calculated to be -72.64%.
Shares Statistics:
A total of 115.65M shares are outstanding, with a floating share count of 85.81M. Insiders hold about 31.15% of the company’s shares, while institutions hold 55.51% stake in the company.
Earnings Estimates
The market rating of Mersana Therapeutics Inc (MRSN) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.17 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$0.63 and -$0.86 for the fiscal current year, implying an average EPS of -$0.79. EPS for the following year is -$0.69, with 5.0 analysts recommending between -$0.18 and -$0.95.
